Abcellera Biologics Stock Price To Book
| ABCL Stock | USD 4.24 0.23 5.15% |
Fundamental analysis of Abcellera Biologics allows traders to better anticipate movements in Abcellera Biologics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Abcellera | Build AI portfolio with Abcellera Stock |
Abcellera Biologics Company Price To Book Analysis
Abcellera Biologics' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Abcellera Biologics Price To Book | 1.24 X |
Most of Abcellera Biologics' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abcellera Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Abcellera Biologics has a Price To Book of 1.2371 times. This is 95.18% lower than that of the Biotechnology sector and 79.52% lower than that of the Health Care industry. The price to book for all United States stocks is 86.99% higher than that of the company.
Abcellera Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abcellera Biologics' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abcellera Biologics could also be used in its relative valuation, which is a method of valuing Abcellera Biologics by comparing valuation metrics of similar companies.Abcellera Biologics is currently under evaluation in price to book category among its peers.
Abcellera Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (14.80) % | ||||
| Current Valuation | 728.16 M | ||||
| Shares Outstanding | 298.48 M | ||||
| Shares Owned By Insiders | 22.96 % | ||||
| Shares Owned By Institutions | 49.00 % | ||||
| Number Of Shares Shorted | 35.72 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 1.24 X | ||||
| Price To Sales | 57.72 X | ||||
| Revenue | 28.83 M | ||||
| Gross Profit | (147.35 M) | ||||
| EBITDA | (204.15 M) | ||||
| Net Income | (162.86 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 65.36 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.43 X | ||||
| Cash Flow From Operations | (108.56 M) | ||||
| Short Ratio | 5.20 X | ||||
| Earnings Per Share | (0.56) X | ||||
| Price To Earnings To Growth | 2.22 X | ||||
| Target Price | 9.14 | ||||
| Number Of Employees | 596 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 1.33 B | ||||
| Total Asset | 1.36 B | ||||
| Retained Earnings | 116.93 M | ||||
| Working Capital | 674.76 M | ||||
| Net Asset | 1.36 B |
About Abcellera Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abcellera Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abcellera Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abcellera Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Abcellera Biologics Piotroski F Score and Abcellera Biologics Altman Z Score analysis. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.